Skip to main content
GutCited

Berberine ： Small Intestinal Bacterial Overgrowth (SIBO)

C

Herbal antimicrobial protocol including berberine showed comparable efficacy to rifaximin for SIBO in retrospective study. Prospective RCT data limited.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dberberine\u0026condition\u003Dsibo'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    


    
    

      Widget powered by
      .
      Free, no account required.
    

  




    








    

        

            C

        

        

            
結論

            
            
Herbal antimicrobial protocol including berberine showed comparable efficacy to rifaximin for SIBO in retrospective study. Prospective RCT data limited.

            
            
        

    










    

  
Key Study Findings





    

        
        

            

                
                    Meta-Analysis
                
                
                n=1552
                
                
                
            

            
                Comparative efficacy of diverse therapeutic regimens for small intestinal bacterial overgrowth: a systematic network meta-analysis.
            
            

                
                Dose: None
                
                
                vs: Multiple comparators (network meta-analysis)
                
                
                Outcome: SIBO eradication rate
                
                
                効果: Berberine highest SUCRA
                
                
                None
                
            

            
            
対象集団: Adults with SIBO from 30 RCTs

            
        

        
        

            

                
                    Randomized Controlled Trial
                
                
                
                2 weeks
                
                
                Open-label
                
            

            
                Berberine and rifaximin effects on small intestinal bacterial overgrowth: Study protocol for an investigator-initiated, double-arm, …
            
            

                
                Dose: 400 mg d
                
                
                vs: control
                
                
                Outcome: a negative breath test
                
                
                効果: None
                
                
                None
                
            

            
            
対象集団: Long-term abdominal discomfort and avoiding excessive examination

            
        

        
    







    
    

        
        

            

  
Key Statistics





            


    

        
2

        
研究数

    

    

        
180

        
参加者数

    

    

        
            
            ↑
            
        
        
Positive

    

    

        C

        
グレード

    




        


        
        
        

            

  
Referenced Papers





            

                
                

                    

                        
                            Comparative efficacy of diverse therapeutic regimens for small intestinal bacterial overgrowth: a systematic network meta-analysis.
                        
                        
                            
                                Other
                            
                            
                            
                        
                    

                    

                        Therapeutic advances in …
                        2025
                        
                    

                

                
                

                    

                        
                            Berberine and rifaximin effects on small intestinal bacterial overgrowth: Study protocol for an investigator-initiated, double-arm, open-label, randomized clinical trial (BRIEF-SIBO …
                        
                        
                            
                                Other
                            
                            
                            
                        
                    

                    

                        Frontiers in pharmacology
                        2023
                        
                        8 件の引用
                        
                    

                

                
            

        

        

        
        
        

            

  
Dosage & Usage





            
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units


            
            

                
一般的な使用量

                

                    
                    

                        
general:

                        
500-1,500 mg/day in divided doses

                    

                    
                    

                        
siboprotocol:

                        
500 mg two to three times daily for 4 weeks (as part of herbal antimicrobial protocol)

                    

                    
                    

                        
giantimicrobial:

                        
500 mg twice daily

                    

                    
                

                
                

                    上限量： Generally well-tolerated up to 1,500 mg/day in divided doses
                

                
            

            

            
            

                
研究で検討された用量

                

                    

                        
                            

                                用量
                                期間
                                効果
                                N
                            

                        
                        
                            
                            

                                None
                                --
                                
                                    
                                    Positive
                                    
                                
                                1552
                            

                            
                            

                                400 mg d
                                2 weeks
                                
                                    
                                    Mixed
                                    
                                
                                --
                            

                            
                        
                    

                

            

            

            
            

                推奨摂取タイミング： With meals; divide doses throughout the day (do not take full daily dose at once)
            

            
        

        

        
        
        

            

  
Safety & Side Effects





            

                
                

                    
報告されている副作用

                    
    
                        
                        
  • 
                            ⚠
                            GI side effects (diarrhea, constipation, flatulence, abdominal pain) — most common
                        
    • 
                        
                        
  • 
                            ⚠
                            May cause uterine contractions (contraindicated in pregnancy)
                        
    • 
                        
                        
  • 
                            ⚠
                            Headache
                        
    • 
                        
                        
  • 
                            ⚠
                            Skin rash (rare)
                        
    • 
                        
                    

                

                

                
                

                    
既知の相互作用

                    
    
                        
                        
  • 
                            ●
                            Diabetes medications (berberine significantly lowers blood sugar; risk of hypoglycemia)
                        
    • 
                        
                        
  • 
                            ●
                            Cyclosporine (berberine inhibits CYP3A4, increasing cyclosporine levels)
                        
    • 
                        
                        
  • 
                            ●
                            Anticoagulants (may have additive blood-thinning effects)
                        
    • 
                        
                        
  • 
                            ●
                            Metformin (additive glucose-lowering effect; monitor closely)
                        
    • 
                        
                        
  • 
                            ●
                            Macrolide antibiotics (berberine inhibits CYP3A4)
                        
    • 
                        
                    

                

                

                
                

                    

                        耐容上限摂取量： Generally well-tolerated up to 1,500 mg/day in divided doses
                    

                

                
            

            

                サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
            

        

        

        
        
        

            

  
Frequently Asked Questions





            




    
    

        
            Does Berberine help with Small Intestinal Bacterial Overgrowth (SIBO)?
            
        
        

            Based on 2 studies with 180 participants, there is limited but promising evidence that Berberine may support Small Intestinal Bacterial Overgrowth (SIBO) management. Our evidence grade is C (Some Evidence).
        

    

    
    

        
            How much Berberine should I take for Small Intestinal Bacterial Overgrowth (SIBO)?
            
        
        

            Studies have used various dosages. A commonly studied range is 500-1,500 mg/day in divided doses. Always consult your healthcare provider before starting any supplement regimen.
        

    

    
    

        
            Are there side effects of Berberine?
            
        
        

            Reported side effects may include GI side effects (diarrhea, constipation, flatulence, abdominal pain) — most common, May cause uterine contractions (contraindicated in pregnancy), Headache, Skin rash (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
        

    

    
    

        
            How strong is the evidence for Berberine and Small Intestinal Bacterial Overgrowth (SIBO)?
            
        
        

            We rate the evidence as Grade C (Some Evidence). This rating is based on 2 peer-reviewed studies with 180 total participants. The overall direction of effect is positive.
        

    

    




        

        

        
        
        

            

  
Related Evidence





            

                
                

                    
に関する他の成分： Small Intestinal Bacterial Overgrowth (SIBO)

                    

                        
                        
                            Partially Hydrolyzed Guar Gum (PHGG)
                            C

                        
                        
                    

                

                

                
                

                    
Berberine 他の症状・状態について

                    

                        
                        
                            Acute Diarrhea
                            C

                        
                        
                        
                            Gut Dysbiosis
                            D

                        
                        
                    

                

                
            

        

        

    


    
    












    

        FDAに関する免責事項:
        これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。